Search results
Neoleukin (NLTX) Stops Development of Lead Drug, Stock Down
Zacks via Yahoo Finance· 1 year agoDue to discontinuing the development of its lead candidate, Neoleukin (NLTX) has no pipeline...
Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) insider upped their holding by 6.7% earlier this year
Simply Wall St. via Yahoo Finance· 2 years agoLooking at Neoleukin Therapeutics, Inc.'s (NASDAQ:NLTX ) insider transactions over the last year, we...
Is Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Invest In Growth?
Simply Wall St. via Yahoo Finance· 4 months agoEven when a business is losing money, it's possible for shareholders to make money if they buy a...
Neoleukin (NLTX) Up 36% on Initiating Another Restructuring Plan
Zacks via Yahoo Finance· 1 year agoNeoleukin (NLTX) seeks strategic options to maximize shareholder's value. This includes the...
We're Keeping An Eye On Neoleukin Therapeutics' (NASDAQ:NLTX) Cash Burn Rate
Simply Wall St. via Yahoo Finance· 2 years agoThere's no doubt that money can be made by owning shares of unprofitable businesses. For example,...
Redmile Group, LLC Boosts Stake in Neoleukin Therapeutics Inc
GuruFocus.com via Yahoo Finance· 9 months agoSan Francisco-based investment firm, Redmile Group, LLC (Trades, Portfolio), recently increased its...
Neoleukin Therapeutics Seeks Strategic Alternatives, To Layoff More In Round 2 Within 6 Months
Benzinga via Yahoo Finance· 1 year agoNeoleukin Therapeutics Inc (NASDAQ: NLTX) has engaged SVB Securities to assist in reviewing...
Neoleukin Pauses Development Of NL-201, Cuts 40% Of Employee Strength
Benzinga via Yahoo Finance· 1 year agoNeoleukin Therapeutics Inc (NASDAQ: NLTX) announced discontinuing the development of NL-201 for...
Neoleukin: Q3 Earnings Snapshot
Associated Press Finance via Yahoo Finance· 6 months agoSEATTLE (AP) — SEATTLE (AP) — Neoleukin Therapeutics, Inc. (NLTX) on Tuesday reported a loss of $4.5 million in its third quarter. On a per-share basis, the Seattle-based company said it had ...
